SBIR Phase I: Endoscopic Probe for Molecular Imaging and Diagnosis of Cancerous Prostate Pathologies

SBIR 第一期：用于分子成像和癌性前列腺病理诊断的内窥镜探针

• 批准号: 2210021
• 负责人: Samuel Rosenthal
• 金额: $ 25.6万
• 依托单位: OPTAVE DIAGNOSTICS LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2210021&HistoricalAwards=false
• 关键词: SBIR; Phase; Endoscopic; Probe; Molecular

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve outcomes for patients with prostate cancer, which affects about one in eight men and is the second deadliest cancer among men. The current process for diagnosing prostate cancer is imprecise and commonly involves multiple rounds of increasingly invasive, uncomfortable, and expensive diagnostic tests. The medical technology proposed in this project will reduce the number of unnecessary biopsies and expensive magnetic resonance imaging tests (MRIs) performed to confirm diagnosis, and enable improved ongoing monitoring of suspected or recovered prostate cancer patients. The proposed device will help hospitals save valuable time and decrease overall costs of care. The device will be designed to address the specific needs of clinicians to accurately diagnose prostate cancer cases at an earlier point in the diagnostic workflow, at a lower cost to health systems. Additionally, the technology will be developed with a focus on cost effectiveness, to ensure increased prostate cancer diagnostic capabilities are accessible even in low-resource settings, such as rural communities and low- and middle-income countries.This Small Business Innovation Research Phase I project will result in a prototype of a new medical device that uses photoacoustic imaging (PAI) and novel acoustic lens technology to aid in detection and diagnosis of prostate cancer. Existing early testing options, such as digital rectal exams, prostate-specific antigen tests, and transrectal ultrasounds, are often inconclusive. The PAI endoscopic probe device proposed in this project will offer hospitals and clinicians a new method for visualizing potentially cancerous prostate tissues, with higher imaging contrast and resolution than existing diagnostics. It will also offer an alternative to other testing methods with known deficiencies that often result in misdiagnosis or missed cases.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的更广泛的影响/商业潜力是改善前列腺癌患者的预后，这会影响大约八分之一的男性，并且是男性中第二个最致命的癌症。当前诊断前列腺癌的过程不精确，通常涉及越来越多的侵入性，不舒服和昂贵的诊断测试。该项目中提出的医疗技术将减少进行不必要的活检的数量和昂贵的磁共振成像测试（MRI），以确认诊断，并能够改善对可疑或恢复的前列腺癌患者的持续监测。拟议的设备将帮助医院节省宝贵的时间并降低整体护理成本。该设备将旨在满足临床医生在诊断工作流程的较早时刻准确诊断前列腺癌病例的特定需求，其卫生系统成本较低。 Additionally, the technology will be developed with a focus on cost effectiveness, to ensure increased prostate cancer diagnostic capabilities are accessible even in low-resource settings, such as rural communities and low- and middle-income countries.This Small Business Innovation Research Phase I project will result in a prototype of a new medical device that uses photoacoustic imaging (PAI) and novel acoustic lens technology to aid in detection and diagnosis of prostate cancer.现有的早期测试选项，例如数字直肠检查，前列腺特异性抗原测试和转直肠超声检查，通常尚无定论。该项目中提出的PAI内窥镜探针装置将为医院和临床医生提供一种可视化潜在癌性前列腺组织的新方法，其成像对比度和分辨率高于现有诊断。它还将提供其他测试方法的替代方法，这些测试方法经常导致误诊或错过案件。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子和更广泛影响的评估评估标准来通过评估来支持的。